BPMC
Blueprint Medicines Corporation · Healthcare · Biotechnology
Momentum inputs (comparable managers):
holder breadth -8.3% ·
share flow -1.2% ·
net new positions -9.1%
· formula
Broad distribution: falling shares and fewer holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2024
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | T. Rowe Price ✦ | 5.39M | -8.3% | $498.32M | 0.1% | ▼ Trim | 2 | SEC ↗ ×2 |
| 2 | Wellington Management ✦ | 3.96M | +22.5% | $366.73M | 0.1% | ▲ Add | 2 | SEC ↗ ×8 |
| 3 | Geode Capital Management ✦ (passive) | 1.48M | +1.4% | $136.94M | 0.0% | ▲ Add | 2 | SEC ↗ ×2 |
| 4 | Millennium Management ✦ | 618.79K | -1.4% | $57.24M | 0.1% | ▼ Trim | 2 | SEC ↗ |
| 5 | Norges Bank ✦ (passive) | 603.23K | +1.9% | $55.80M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 6 | Fisher Asset Management ✦ | 335.35K | -0.2% | $31.02M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 7 | Marshall Wace ✦ | 333.77K | -5.1% | $30.87M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 8 | D. E. Shaw & Co. ✦ | 255.69K | -15.5% | $23.65M | 0.0% | ▼ Trim | 2 | SEC ↗ ×2 |
| 9 | Renaissance Technologies ✦ | 174.50K | +58.1% | $16.14M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 10 | AQR Capital Management ✦ | 114.06K | +46.0% | $10.55M | 0.0% | ▲ Add | 2 | SEC ↗ ×3 |
| 11 | Citadel Advisors ✦ | 77.86K | +98.6% | $7.20M | 0.0% | ▲ Add | 2 | SEC ↗ ×2 |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| Point72 Asset Management | $54.06M | was 0.2% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 2 holders, 301 shares, $38,583 reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.